{"component": "definition", "props": {"groups": [{"size": 5, "snippet": "means the preliminary research plan attached hereto as Exhibit A, which plan sets forth (a) the activities of the Parties commencing on the Effective Date until the Final Target Selection Date, including the Collaboration Target selection process, Screening Assays to be conducted, and contemplated time periods associated with such activities, and (b) a general description of the types of activities to be conducted by the Parties during the remainder of the Collaboration Term. For purposes of clarity, upon final JSC approval of the Research Plan with respect to any Program, the terms of such Research Plan shall supersede the terms of the Initial Research Plan with respect to such Program.", "snippet_links": [{"key": "preliminary-research", "type": "clause", "offset": [10, 30]}, {"key": "exhibit-a", "type": "clause", "offset": [55, 64]}, {"key": "activities-of-the-parties", "type": "clause", "offset": [96, 121]}, {"key": "commencing-on-the-effective-date", "type": "clause", "offset": [122, 154]}, {"key": "the-final", "type": "clause", "offset": [161, 170]}, {"key": "selection-date", "type": "definition", "offset": [178, 192]}, {"key": "target-selection-process", "type": "clause", "offset": [222, 246]}, {"key": "time-periods", "type": "clause", "offset": [299, 311]}, {"key": "associated-with", "type": "definition", "offset": [312, 327]}, {"key": "description-of-the", "type": "definition", "offset": [363, 381]}, {"key": "types-of-activities", "type": "clause", "offset": [382, 401]}, {"key": "by-the-parties", "type": "clause", "offset": [418, 432]}, {"key": "collaboration-term", "type": "clause", "offset": [461, 479]}, {"key": "for-purposes-of", "type": "clause", "offset": [481, 496]}, {"key": "approval-of", "type": "definition", "offset": [521, 532]}, {"key": "the-research", "type": "clause", "offset": [533, 545]}, {"key": "with-respect-to", "type": "clause", "offset": [551, 566]}, {"key": "the-terms", "type": "definition", "offset": [580, 589]}, {"key": "terms-of-the", "type": "clause", "offset": [632, 644]}], "samples": [{"hash": "jXarcyyTxOx", "uri": "/contracts/jXarcyyTxOx#initial-research-plan", "label": "Product Development and Commercialization Agreement (Regulus Therapeutics Inc.)", "score": 23.71321013, "published": true}, {"hash": "7LhGaAWILVC", "uri": "/contracts/7LhGaAWILVC#initial-research-plan", "label": "Product Development and Commercialization Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989049, "published": true}, {"hash": "582XcPEuftW", "uri": "/contracts/582XcPEuftW#initial-research-plan", "label": "Product Development and Commercialization Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "29fd49f0a4a03513f46f862cc0af10e5", "id": 1}, {"size": 4, "snippet": "has the meaning set forth in Section 4.4.1.", "snippet_links": [{"key": "section-441", "type": "clause", "offset": [29, 42]}], "samples": [{"hash": "i9AXpVBu7x3", "uri": "/contracts/i9AXpVBu7x3#initial-research-plan", "label": "Collaboration and License Agreement (Precision Biosciences Inc)", "score": 33.4681724846, "published": true}, {"hash": "kPm0GNzrycm", "uri": "/contracts/kPm0GNzrycm#initial-research-plan", "label": "Development and License Agreement (Precision Biosciences Inc)", "score": 32.2087611225, "published": true}], "hash": "d9187d06c774722faffc1b1e27fbcf00", "id": 2}, {"size": 3, "snippet": "means the initial research plan of the Company.", "snippet_links": [{"key": "of-the-company", "type": "clause", "offset": [32, 46]}], "samples": [{"hash": "fResxAlrvtS", "uri": "/contracts/fResxAlrvtS#initial-research-plan", "label": "Option Agreement (Century Therapeutics, Inc.)", "score": 32.4031485284, "published": true}, {"hash": "5ZApPC9MSxC", "uri": "/contracts/5ZApPC9MSxC#initial-research-plan", "label": "Commitment Agreement (Arvinas, Inc.)", "score": 28.5906913073, "published": true}, {"hash": "67EaGSk7IS1", "uri": "http://ir.arvinas.com/static-files/336b634f-4249-4c72-9e4b-12340fb3bfb0", "label": "ir.arvinas.com", "score": 10.1704312115, "published": false}], "hash": "65a49c64723c017a491b19176d4395e2", "id": 3}, {"size": 3, "snippet": "shall have the meaning set forth in Section 3.2.1.", "snippet_links": [{"key": "section-321", "type": "clause", "offset": [36, 49]}], "samples": [{"hash": "fMMVnHcAB00", "uri": "/contracts/fMMVnHcAB00#initial-research-plan", "label": "Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 24.6221765914, "published": true}, {"hash": "j20yEdcksds", "uri": "/contracts/j20yEdcksds#initial-research-plan", "label": "Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 24.5646817248, "published": true}], "hash": "72b824b4d4d792ab3e07339919e7c031", "id": 4}, {"size": 2, "snippet": "has the meaning set forth in the definition of \u201cResearch Plan.\u201d", "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [29, 46]}, {"key": "research-plan", "type": "clause", "offset": [48, 61]}], "samples": [{"hash": "2zDocvFR88p", "uri": "/contracts/2zDocvFR88p#initial-research-plan", "label": "Collaboration and License Agreement (Caribou Biosciences, Inc.)", "score": 32.4962354552, "published": true}, {"hash": "7GXljjbbvUS", "uri": "/contracts/7GXljjbbvUS#initial-research-plan", "label": "Collaboration and License Agreement (Caribou Biosciences, Inc.)", "score": 32.3456536619, "published": true}], "hash": "036964e322d125901b7d155a5a9675d0", "id": 5}, {"size": 2, "snippet": "means the CUE-101 Initial Research Plan, the CUE-102 Initial Research Plan, the CUE-103 Initial Research Plan and all other initial Research Plans for Additional Alleles and the [***] Allele that are deemed Initial Research Plans in accordance with Section 4.3(f), as applicable.", "snippet_links": [{"key": "research-plans", "type": "definition", "offset": [132, 146]}, {"key": "in-accordance-with", "type": "definition", "offset": [230, 248]}], "samples": [{"hash": "8B6kp6uVxAx", "uri": "/contracts/8B6kp6uVxAx#initial-research-plan", "label": "Collaboration, License and Option Agreement (Cue Biopharma, Inc.)", "score": 29.9828884326, "published": true}, {"hash": "d2XFhoyUloe", "uri": "/contracts/d2XFhoyUloe#initial-research-plan", "label": "Collaboration, License and Option Agreement (Cue Biopharma, Inc.)", "score": 29.8651608487, "published": true}], "hash": "07566fc656161b4a994086a6545a3abb", "id": 6}, {"size": 1, "snippet": "has the meaning set forth in Section 4.1 (Research Plan). 1.90. \u201cInternal Compliance Codes\u201d means a Party\u2019s internal policies and procedures intended to ensure that such Party complies with Applicable Laws, Party-Specific Regulations, and such Party\u2019s internal ethical, medical, and similar standards. 1.91. \u201cInvus\u201d has the meaning set forth in Section 1.12 (Affiliate). 1.92. \u201cJoint Arising Know-How\u201d has the meaning set forth in Section 8.2.3 (Joint Arising Technology). 1.93. \u201cJoint Arising Patent Rights\u201d has the meaning set forth in Section 8.2.3 (Joint Arising Technology). 1.94. \u201cJoint Arising Technology\u201d has the meaning set forth in Section 8.2.3 (Joint Arising Technology). 1.95. \u201cJSC\u201d has the meaning set forth in Section 3.1 (Joint Steering Committee). 1.96. \u201cJSC Chair\u201d has the meaning set forth in Section 3.1 (Joint Steering Committee). 1.97. \u201cKnow-How\u201d means all commercial, technical, scientific, and other know-how and information, in each case, that is not in the public domain or otherwise publicly known, including concepts, strategies, models, instructions, materials, protocols, inventions, discoveries, trade secrets, knowledge, technology, methods, processes, practices, formulae, amino acid sequences, nucleotide sequences, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, and data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing, and quality control data and know how, including regulatory data, study designs, and protocols), in all cases, whether or not patentable and in written, electronic, or any other form now known or hereafter developed, but expressly excluding all Patent Rights. For clarity, Know-How includes any such information comprised or embodied in any applicable physical materials but excludes Patent Rights. 1.98. \u201cLexicon\u201d has the meaning set forth in the preamble. 15 1.99. \u201cLexicon Arising Know-How\u201d has the meaning set forth in Section 8.2.1 (Lexicon Arising Technology). 1.100. \u201cLexicon Arising Patent Right\u201d has the meaning set forth in Section 8.2.1 (Lexicon Arising Technology). 1.101. \u201cLexicon Arising Technology\u201d has the meaning set forth in Section 8.2.1 (Lexicon Arising Technology). 1.102. \u201cLexicon Indemnitees\u201d has the meaning set forth in Section 11.2 (Indemnification by Novo Nordisk). 1.", "snippet_links": [{"key": "section-41", "type": "clause", "offset": [29, 40]}, {"key": "research-plan", "type": "clause", "offset": [42, 55]}, {"key": "internal-compliance-codes", "type": "definition", "offset": [65, 90]}, {"key": "a-party", "type": "clause", "offset": [98, 105]}, {"key": "internal-policies-and-procedures", "type": "clause", "offset": [108, 140]}, {"key": "to-ensure", "type": "clause", "offset": [150, 159]}, {"key": "such-party", "type": "clause", "offset": [165, 175]}, {"key": "with-applicable-laws", "type": "clause", "offset": [185, 205]}, {"key": "specific-regulations", "type": "definition", "offset": [213, 233]}, {"key": "section-823", "type": "clause", "offset": [431, 444]}, {"key": "joint-arising-technology", "type": "definition", "offset": [446, 470]}, {"key": "joint-arising-patent-rights", "type": "definition", "offset": [480, 507]}, {"key": "section-31", "type": "clause", "offset": [725, 736]}, {"key": "joint-steering-committee", "type": "definition", "offset": [738, 762]}, {"key": "jsc-chair", "type": "definition", "offset": [772, 781]}, {"key": "and-information", "type": "clause", "offset": [933, 948]}, {"key": "each-case", "type": "definition", "offset": [953, 962]}, {"key": "in-the-public-domain", "type": "definition", "offset": [976, 996]}, {"key": "publicly-known", "type": "definition", "offset": [1010, 1024]}, {"key": "trade-secrets", "type": "definition", "offset": [1127, 1140]}, {"key": "amino-acid", "type": "clause", "offset": [1206, 1216]}, {"key": "technical-assistance", "type": "clause", "offset": [1316, 1336]}, {"key": "computer-programs", "type": "definition", "offset": [1378, 1395]}, {"key": "data-and-results", "type": "clause", "offset": [1417, 1433]}, {"key": "control-data", "type": "clause", "offset": [1598, 1610]}, {"key": "regulatory-data", "type": "clause", "offset": [1635, 1650]}, {"key": "in-all-cases", "type": "clause", "offset": [1683, 1695]}, {"key": "for-clarity", "type": "clause", "offset": [1846, 1857]}, {"key": "such-information", "type": "definition", "offset": [1881, 1897]}, {"key": "physical-materials", "type": "definition", "offset": [1938, 1956]}, {"key": "the-preamble", "type": "clause", "offset": [2030, 2042]}, {"key": "section-821", "type": "clause", "offset": [2109, 2122]}, {"key": "indemnification-by-novo-nordisk", "type": "clause", "offset": [2445, 2476]}], "samples": [{"hash": "btPrUnhfEcZ", "uri": "/contracts/btPrUnhfEcZ#initial-research-plan", "label": "Exclusive License Agreement (Lexicon Pharmaceuticals, Inc.)", "score": 33.3648186174, "published": true}], "hash": "57ddab1fed4b4534b927c031d70f4430", "id": 7}, {"size": 1, "snippet": "means (a) the initial plan for carrying out the research activities of Syros and its Affiliates during the Research Term and (b) a high-level summary of the research activities of Incyte and its Affiliates during and after the Research Term, in relation to any Program Target other than a Validated Target, including, in each case, ((a) and (b)): [**]. The Initial Research Plan is attached hereto as Schedule 1.85.", "snippet_links": [{"key": "initial-plan", "type": "definition", "offset": [14, 26]}, {"key": "research-activities", "type": "definition", "offset": [48, 67]}, {"key": "during-the-research-term", "type": "clause", "offset": [96, 120]}, {"key": "summary-of-the", "type": "clause", "offset": [142, 156]}, {"key": "after-the-research-term", "type": "clause", "offset": [217, 240]}, {"key": "in-relation-to", "type": "clause", "offset": [242, 256]}, {"key": "program-target", "type": "definition", "offset": [261, 275]}, {"key": "validated-target", "type": "definition", "offset": [289, 305]}, {"key": "each-case", "type": "definition", "offset": [321, 330]}], "samples": [{"hash": "dWi24UIfeby", "uri": "/contracts/dWi24UIfeby#initial-research-plan", "label": "Target Discovery, Research Collaboration and Option Agreement (Syros Pharmaceuticals, Inc.)", "score": 29.1916495551, "published": true}], "hash": "a9d2a0f653394ae6e3d31855be9616d0", "id": 8}, {"size": 1, "snippet": "is defined in Section \u200e3.3. The Initial Research Plans are provided in Exhibit A and Exhibit B.", "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}, {"key": "research-plans", "type": "definition", "offset": [40, 54]}, {"key": "exhibit-a", "type": "clause", "offset": [71, 80]}], "samples": [{"hash": "l4XpingNeaf", "uri": "/contracts/l4XpingNeaf#initial-research-plan", "label": "Collaboration and License Agreement (Xencor Inc)", "score": 30.3497604381, "published": true}], "hash": "6d7ef6d6f85fcbdbb5b55cf0e5809e11", "id": 9}, {"size": 1, "snippet": "shall have the meaning given to such term in Section 4.1.4(a). 1.89 \u201cInitiation\u201d, \u201cInitiated\u201d or \u201cInitiate\u201d means, with respect to a Clinical Trial, the first dosing of the first human subject in such Clinical Trial with the Collaboration Product being studied under such Clinical Trial. 1.90 \u201cInvention\u201d means any Know-How, whether or not patentable, in each case that is first conceived, discovered, invented, made or conceived and reduced to practice by or on behalf of a Party (or their respective Affiliates) (whether solely by or on behalf of a Party (or its Affiliate) or jointly by or on behalf of the Parties (or their respective Affiliates)) in accordance with this Agreement.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [115, 130]}, {"key": "clinical-trial", "type": "clause", "offset": [133, 147]}, {"key": "first-dosing", "type": "definition", "offset": [153, 165]}, {"key": "human-subject", "type": "definition", "offset": [179, 192]}, {"key": "collaboration-product", "type": "definition", "offset": [225, 246]}, {"key": "each-case", "type": "definition", "offset": [355, 364]}, {"key": "to-practice", "type": "clause", "offset": [442, 453]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [454, 472]}, {"key": "a-party", "type": "clause", "offset": [473, 480]}, {"key": "respective-affiliates", "type": "definition", "offset": [491, 512]}, {"key": "of-the-parties", "type": "clause", "offset": [603, 617]}, {"key": "in-accordance-with", "type": "definition", "offset": [652, 670]}, {"key": "this-agreement", "type": "clause", "offset": [671, 685]}], "samples": [{"hash": "keLi1TxweZy", "uri": "/contracts/keLi1TxweZy#initial-research-plan", "label": "License and Collaboration Agreement (C4 Therapeutics, Inc.)", "score": 33.1409993155, "published": true}], "hash": "f629e08d5047eeb1cee34b4dcb0bd9aa", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIeaW5pdGlhbC1yZXNlYXJjaC1wbGFuIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 25, "snippet": "means the preliminary research plan attached hereto as Exhibit A, which plan sets forth (a) the activities of the Parties commencing on the Effective Date until the Final Target Selection Date, including the Collaboration Target selection process, Screening Assays to be conducted, and contemplated time periods associated with such activities, and (b) a general description of the types of activities to be conducted by the Parties during the remainder of the Collaboration Term. For purposes of clarity, upon final JSC approval of the Research Plan with respect to any Program, the terms of such Research Plan shall supersede the terms of the Initial Research Plan with respect to such Program.", "title": "Initial Research Plan", "id": "initial-research-plan", "examples": ["The CUE-103 <strong>Initial Research Plan</strong> shall, at a minimum, unless the Parties agree otherwise, be reasonably designed to include Research activities for CUE-103 Compounds containing the Initial Collaboration Allele(s) reasonably required to accomplish the filing of an IND [**] and shall be consistent with the Template <strong>Initial Research Plan</strong>.", "The CUE-103 <strong>Initial Research Plan</strong> shall be updated and amended by the JRC as it deems appropriate, and in any event promptly after any LGC Additional Allele, Cue Additional Allele [**] is added to the CUE-103 Program in accordance with the terms of Section 4.3(e).", "For clarity, and without limiting the Parties\u2019 ability to amend the Research Plan pursuant to Section 3.2.2 (<strong>Initial Research Plan</strong>; Amendments to the Research Plan), the Development Plan pursuant to Section 6.3.2 (Initial Development Plan; Amendments to the Development Plan) or the Commercialization Plan pursuant to Section 8.3.2 (Initial Commercialization Plan; Amendments to the Commercialization Plan), [***], as applicable, may not [***].", "The <strong>initial Research Plan</strong>, including the initial Research Budget, is attached hereto as Schedule 3.2.2 (<strong>Initial Research Plan</strong> and Research Budget).", "The screening requirements outlined in the <strong>Initial Research Plan</strong> shall be sufficient to satisfy the Completion of Screening requirement under this Section 2.7 and screening of such Targets shall be deemed complete for purposes of clause (i) of Section 2.7.1 above when CK has generated that number of Data Points specified by the <strong>Initial Research Plan</strong> for Contract Years [*] through [*], including those Data Points generated by CK prior to the Effective Date, or such lesser number as the JRC may agree.", "The <strong>initial Research Plan</strong> shall be established by the mutual agreement of the Parties immediately upon the execution of this Agreement (the &quot;<strong>Initial Research Plan</strong>&quot;) and shall cover the period from the Effective Date through December 31, 2001 in detail and includes general plans for the following two (2) years.", "GSK shall supply to CK such number of chemical entities and in such quantities as required by the <strong>Initial Research Plan</strong> (as defined in Section 2.3.2) in time for the scheduled screening against a particular Mitotic Kinesin Target prior to the end of Contract Year [*].", "In the event of any express conflict or inconsistency between this Agreement and the <strong>Initial Research Plan</strong>, any Research Plan or any Early Development Plan or of any Schedule or Exhibit hereto, the terms of this Agreement and of the Side Agreement shall control.", "During the visits, Omeros representatives may examine all Records and Materials, facilities and equipment that pertain to the Services and Deliverables, and any other relevant resources pertaining to the <strong>Initial Research Plan</strong> and any Additional Research Plan(s), as well as any other audit reports prepared by or on behalf of Affitech with respect to quality audits of such relevant resources.", "The JAC shall be formed within [\u2020] from the Effective Date and remain active until (i) completion of the <strong>Initial Research Plan</strong> and any Additional Research Plan(s)or (ii) termination of the Agreement, whatever event occurs first."], "related": [["research-plan", "Research Plan", "Research Plan"], ["development-plan", "Development Plan", "Development Plan"], ["research-budget", "Research Budget", "Research Budget"], ["research-program", "Research Program", "Research Program"], ["research-project", "Research Project", "Research Project"]], "related_snippets": [], "updated": "2025-07-07T00:35:48+00:00"}, "json": true, "cursor": ""}}